Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPR1 | P16066 | 9/20 | 0.45 |
| ▸ | GABBR2 | O75899 | 5/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178685 | 0.84 | CYP1A2 (0.60) | USP2CYP1A2CYP3A4CYP2C19CLK4 | |
| SCHEMBL4174678 | 0.84 | GABBR2 (0.41) | NPR1GABBR2GABBR1USP2CYP1A2 | |
| SCHEMBL4185455 | 0.82 | CYP1A2 (0.57) | USP2CYP1A2CYP3A4CYP2C19CLK4 | |
| SCHEMBL4184097 | 0.79 | IRAK4 (0.47) | NPR1GABBR2GABBR1USP2CYP1A2 | |
| SCHEMBL4186187 | 0.78 | NPR1 (0.45) | NPR1GABBR2GABBR1USP2CYP1A2 | |
| SCHEMBL4184296 | 0.77 | NPR1 (0.46) | NPR1GABBR2GABBR1USP2CYP1A2 | |
| SCHEMBL4184674 | 0.77 | IRAK4 (0.47) | NPR1GABBR2GABBR1USP2CYP1A2 | |
| SCHEMBL4191073 | 0.77 | IRAK4 (0.47) | NPR1GABBR2GABBR1USP2CYP1A2 | |
| SCHEMBL4173545 | 0.77 | DYRK1A (0.49) | USP2CYP1A2CYP3A4CYP2C19CLK4 | |
| SCHEMBL4177795 | 0.77 | CYP1A2 (0.48) | USP2CYP1A2CYP3A4CYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | claimed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | NPR1 645/4885GABBR2 85/4885GABBR1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.